Subscribe for news from Oncology Venture here
OV announces merger plans between Oncology Venture and Medical Prognosis Institute
OV announces positive interim results from a phase 2 study with LiPlaCis and its DRP in heavily pretreated metastatic breast cancer patients
The rights issue of Oncology Venture is oversubscribed
Read article about Oncology Venture from Børsen
Oncology Venture will execute license to multi TKI phase 3 compound
Notice of extraordinary general meeting in Oncology Venture Sweden AB
Oncology Venture publishes Interim Report Q3 2017
Decision on rights issue subject to approval at Extraordinary General Meeting
Aktietorgets feed to the OV’s web-page is not working,
Check trading in Oncology Venture’s share on Nordnet.se
Successful inclusion in Phase 2 of LiPlaCis for metastatic Breast cancer
LiPlaCis Phase 2: Relevant Clinical Benefits in 3 out of 5 Treated Patients
Oncology Venture publishes Half-year Report 2017
Oncology Venture annonces Pipeline update
2X Oncology’s chief executive officer, George O. Elston’s letter to shareholders
MedWatch article from 3 August 2017
Lovende studie bringer Oncology Venture nærmere første lægemiddel (Danish)
Oncology Venture närmar sig sitt första läkemedel efter en lovande studie (Swedish)
Aktieinfo publishes analysis on Oncology Venture
Successful DRP prediction of patients treated with 2X-121, the PARP inhibitor from Eisai
Oncology Venture to evaluate Phase 3 product from Novartis
Oncology Venture and Eisai Forge Exclusive Global License Agreement for Clinical Stage Oncology Drug PARP Inhibitor E7449 / 2X-121
Successful prediction of Cancer response to LiPlaCis in Breast cancer and other tumors by OV’s DRP
OV`s second drug candidate in the clinic – First Multiple Myeloma patient in study with APO010
2X Oncology obtains US IND for 2X-111 a Liposomal doxorubicin
The efficacy of chemotherapy with epirubicin, one the of most used drugs in Breast Cancer can now be predicted by the DRP
2X Oncology Inc. presents at Jefferies Global Healtcare conference (live webcast)
Berlingske Business: Interview with CEO of Oncology Venture
Interview with OV and MPI in ‘Millionærklubben’
Latest articles from MedWatch (Danish)
VD Peter Buhl video presentation at Sedermeradagen in Copenhagen 23. March
Oncology Venture secures seed financing for two SPVs & DRP Exclusivity
Oncology Venture: First DRP-positive breast cancer patient obtained reduction of tumor
Oncology Venture: Best Practice article on APO010
Presentation of OV by CEO Peter Buhl Jensen
Smallcap.se analysis of Oncology Venture
Peter Buhl Jensen talks about Oncology Venture – Radio24syv
